director

product

Cassava Sciences Inc

action

The day to day price action of this limp dick is more painful to watch than slugs breeding.

$SAVA , this daily one way action is depressing.

Zero confidence in management based on both recent actions and historical issues with the FDA. 2.

$SAVA We may get frustrated with volatility, manipulation, and irregular daily price action

price

This is sickening that these crooks can manipulate the price like this. !!!

He invites shorts to destroy stock price.. pathetic!

Some had to drop in price a little first!

new employee mr. cook must be pissed as this is lower price than the shares he got it for.

All.u did was dilute the pps 
..and release to prs to kill the stock price and momentum  
 You did so well..you fxuking scumbag.

I hate the stock price runup leading to an announcement.

data

- 
$AVXL in comparison, boring as hell - whenever Missling talks people fall asleep and holding back data and further readouts without any logical explanation are red flags -

$SAVA 
Pyggie here was bullish a few days ago, folded like a pussy because he can’t read data, and now spews FUD, like a spoiled child, because he’s worried he may have paper-handed a monster.

but offer only the “opinion” that there was “possible data manipulation.”

$SAVA longtime biotech investor and my honest experience when a CEO promises good data and there is a long waiting period = not good.

Sentiment matters in this game, and unfortunately, this company has been drug through the mud for so long that good data might just get overlooked.

$SAVA The ironic and sad thing is that this ticker has been abused and manipulated so badly that even if it triples on upcoming data release it still won&#39;t come close to ATH achieved on much less evidence of safety and efficacy.

The CEO belongs in jail with all this pump and dump stock manipulation and data manipulation

just annoying we all get so worked up and insulting when we, the retail investor, can neither move Remi to release data early or in truth, move the SP by buying or selling a few hundred shares.

$SAVA dumb management causing longs to lose confidence, you dont change the date of data release every few weeks, just give a date when you are certain and stick with that, its that simple

BIIB with a 27% chance of no decline - so bad, how can they even publish data like that.

patient

however, if you are a family member of Alz patient think about how fatiguing emotionally and financially it is to change diapers, have your name forgotten, or even have to take a license away from an otherwise healthy person.

but your day will come when you will pay back way more than the damage you have caused and the lives you have threatened from being treated for a debilitating disease.

$ALZN $ATHA $ORMP $SAVA $SPRC yes then go back to your scam board clown no need to trap others in this scam .. we know what value SAVA brings to their AD patients

Lecanemab approved - IV  infusion..increased infection risk, inconvenient for patients with MD&#39;s fully aware 
of side effects: brain swelling and bleeding. 2.

Eventually, the  
AD patient is unable to perform daily functions.

But the monoclonal antibody treatment also carries risks of brain swelling and bleeding.

$BIIB - lied and tried to push their bad drug Aduhelm on unsuspecting patients (one of which is a family member of mine).

3 deaths in 1900 trial patients.. how many deaths is our FDA going to inflict on millions of folks who are supposed to take this death drugs that also happen to have near-zero efficacy?? SMH

Avxl, not good they didn&#39;t have an agreement in place “plan for approval“ before they started the test fase 2b 500 patients.

$SAVA It&#39;s not only CRUEL for anyone to be prescribing any of these MABs for AD patients, it&#39;s impractical for both patients and the healthcare system in general.

application

$SAVA Words  to  to  ignorant,  never  hype  a  employee  from  fda,  shady  shiat! 🤡🤡🤡😂😂😂

It doesn&#39;t matter if drugs for terminal illnesses, have been approved after 6 months, because there is endless manipulation here, and this waiting game is based on either FDA approval or denial based on corruption at the agency?

This is such crap with the FDA my Father died a year ago from it

$BIIB $SAVA You would need uncommon patience to not be crazy mad at the system for this shenanigan approval process and decision from the FDA.

Idiots with no respect for integrity continues  to run 
wild within the FDA.

$SAVA once again we got fu*ked by the evil BIIB + FDA.

$SAVA THIS is how corrupt our FDA and state medical boards are.

$BIIB $SAVA  
I tell ya why - FDA is corrupt deep in its root, period!

$SAVA HUGE multi million dollar purchase by key Director is a more than interesting indicator of good news to come IMHO

no more speculation, now it&#39;s real, two FDA approved meds, two major products, top of the line in comparison of their rivals, for cheaper price, AND WITH NO MUCH COMPETITION!

14 years later, stand behind and present your product with vigor and passion not an alcoholics enthusiasm. Do.

but even better to see the science underneath the product becoming more and more studied in a variety of ways.

Their product works (see the mad Pole Piotr’s graphs 😵‍💫)
Multi year holds, the bodadem.

This share price is a steal with those great Levo results this morning, and their other 3 approved and growing products.

$ENSC 8mil mcap, just patents alone is worth 100mill ++ 
Product showing better results than OxyContin.

business-result

But the company actually has never seen before wonderful results.

And, make no mistake, the result are impressive.

It is the best results that have been seen in AD.

This could be huge in eliminating artificial FUD against the top-line results.

$SAVA Market is moving higher as SAVA is expecting data results.

Anavex is late like the sun comes up and still produces great results.

MOST IMPORTANTLY, THE RESULTS MUST HAVE BEEN GOOD AND PROMISING at each snapshot that leads Remi to use the word &quot;Thrilled&quot; in Dec 6 PR.

Data tells me no safety issues, with a possible large therapeutic window.

Then they dropped the “good” totally “not disappointing” data that Remi was so “Thrilled” about.

This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA

SAVA data gets analyzed by multiple different labs and shows its cognition improvement in mild AD cases, safe and well-tolerated

$SAVA I love not being able to hold $28 off data that will keep it pinned here until 2024.

but the data to date would predict continued efficacy that will be nigh on impossible to ignore.

$SAVA Institutional buying says data is good!! !

I’ll keep buying until data comes out…

Excited for the next data unveiling….bring it on!

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

This will bring in billions of revenue and it will make the life quality longer for AD patients.

This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.

CURING LEUKEMIA isn&#39;t a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

The high number of the patients that went into CMS (which is 80% complete) is reassuring.

but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!

but mostly new hope for all the families and patients with AZ.

Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.

Adamis Pharmaceuticals Corp

Our engine estimates this stock s price action will have a sharp negative trend in the short-term and has a negative long-term outlook $ADMP

Now with the price where it is, the “plan” simply will not work.

Anyone following this ticker knows the share price was severely depressed because the company had no runway.

Reverse split and shell game continues, share price gets annihilated further. 2.

Forget about those prices, you won’t see it again.

Read the article during the day that one of our collegues in here shared, prices are very high for the Epipen since they have troubles to respond to the demand, basicly a shortage.

Now read the last part of that article: “The disconnection was: Does a quality control issue at a single manufacturing site warrant an 80% haircut to a price target?

but I’ve been wrong so far with this but I still easily talk myself into adding at this ridiculous price

DOUBLE price from what market thinks it worth.

$ADMP buyout price of $10 and l shit myself

show

$ADMP Every week this becomes more and more a shit show!!!! !

Just Fing end this endless ADUMPY Shit show and provide some relief to all the multi year huge bagholders.

$ADMP   Cancel this shit show or give me 2 dollars ashare right now!

$ADMP the never ending shit show continues….

but wow, bag holders, kill the vibe in here… idk

$ADMP  another pure trash stock you guys pick some stock that will tank as fast as it go up WOW

Hahaha wow nobody cares about this pile of crap… 
80 freekin shares

$ADMP wow management destroyed this company’s prospects.

$ADMP  
 
Wow this has gone to bad to worse.

news

$ADMP Not exactly the news we been waiting for.

all Gains lost from extention news.. they lasted all of about 3 minutes!

$ADMP no news another disappointing Monday and it’s green not red while the broad market is red.

Let&#39;s say we are all screwed after the worst news one could expect.

Nothing , no deal , SP is shit , volume is shit , no news since 3 months.

We’ve got wed-Fri, and new 🆙 short vol… we never get timely news.

$ADMP lmao of course they got the news days ago and waited until aftermarket to drop the news, this company never does anything “timely”.

Bad news after bad news, delays after delays, wrong decisions at every step they took.

$ADMP no news, no BO, jack shit nothing this year! !

post

$ADMP it’s kinda disgusting that they stick their heads out from under a rock to announce the merger proposal and post a creepy video.

$ADMP Definition of insanity: posting the same memes and messages, day after day, and expecting a different result.

normally between holding hands and making out with @sheeladipo hes posting more of his bullshit lies about taking Tempol or how he doest have AIDS…  
you know just lie after lie

Post 5 times in a row and says absolutely nothing of any substance!!

I must say that much of this forum (except a handful of good people here) is morally corrupt for not regulary flagging vulgar posts.

i see a lot of whining in here, soon i&#39;ll just get fed up and just stay away from this chat, terribly negative, non realistic comments, trolls are a cancer in this chat.

this shill has been posting nonsense like this for years…  pathetic

first time i write directly to you folks : i can not understand why, the company i mentioned at the beginning of this post, is not more than 16 cents!

$ADMP i ask where the twitter posts are and then they suddenly tweet, weird.

Jake Nichols, a pharmacist who recovered from opioid addiction, is now the Director of Regulatory affairs at USWM.. a truly amazing story!

I don’t know, it’s crazy.. Opioid addition is no joke, and this product will save lives!

$ADMP Literally saving lifes and this management only trying to screw shareholders instead of selling this product to every family, everywhere and getting contracts from goverments.

Just so happy we have USWM to sell our product 😩🔫

Both provide a vital need for navigating the critical shortage of self-injectable, life-saving products with a compact and user-friendly design.

here WE own two amazing products, not speculative, fda approved.

life

Zimhi, loved by the professionals on the ground, game changer in the saving lifes cause, mainly fentanyl overdoses.

Zimhi is a unique product, top of the line, huge market, huge, droga more droga = more overdoses, more lives to safe.

line

any shares you purchase at the GOLD LINE is literally GOLD!

All i know, we have the best meds for overdoses, and top of the line Epipen competitor.

Not speculative pharma, a real pharma, FDA approved products, which two are top of the line, 1 is a game changer in the opioids overdoses, Zimhi, Google it, half a billion market ! Yes!

$ADMP $BIIB i keep insisting, this is NOW a serious pharma player, game changer products, FDA APPROVED, 2 top of the line products.

look into Adamis Pharma, no more speculation, now it&#39;s real, two FDA approved meds, two major products, top of the line in comparison of their rivals, for cheaper price, AND WITH NO MUCH COMPETITION!

$ADMP Why we are going up… FDA meeting next week( Feb-15) over naloxone OTC application… This will increase our market in the future! WOW!!!

It is the best option, aside from taking three-four years to go through the FDA regulatory process to develop a Zimhi competitor.

Amyris Inc

partner

He has a history of being a bad partner and they also may not want to get into bed with a company with a balance sheet like this.

$IBRX $AMRS Bad news from our partner ImmunityBio.

Partner with more celebs and bring more unprofitable derivative products to market!

world

It&#39;s fake because in the real world it doesn&#39;t exist!!!

fund

&quot;Amyris: In Danger Of Running Out Of Funds After Delay To Key Strategic Transaction&quot; 
 
Suspicious is that negative reports about AMRS at SA are always freely accessible and you do not need a subscription.

$VKTX i moved all my funds from here to $AMRS … what a failure I am ..! !

But many, it has been brutal over the past year and no sign of it stopping: 
 
Cathie Wood’s popular ARK Innovation ETF to a new 30-month trading low on Tuesday after the innovation-based fund ended in negative territory for the third straight session.

trading

$AMRS trading 101 .. always the same nonsense dip, keeping it in check. This time was bit boring slow, stealing shares :)

• $AMRS – fell 23.5% to $1.98 in pre-market trading after the company reported worse-than-expected Q3 results 
• $CARG - shares fell 23% to $10.60 in pre-market trading after the company reported worse-than-expected Q3 results.

In the real world of trade, selling non existing goods is called fraud!!!

afterhours

These directors that Amyris hired from Walmart are doing wonders and pushing more SKUs into Walmart.

I appreciated that he mentioned that the Board of Directors was involved in the decision making processes, it was obvious,

Terasana is probably a very good product,

This brand is growing extremely naturally and when mom’s approve of a product they tend to spread like wildfire and we’re seeing that.

Just disaster after disaster, it&#39;s unbelievable when the products are just so incredible.

They do have more than enough for now .. and more R&amp;D is coming, plus the steady product sales revs.

This shelf has been restocked which means 4U by Tia is selling pretty good (better than any other consumer product Amyris ever developed) and the company did not run out of cash.

I should add that the product seems fine, fast and free shipping, well packaged, fair price… why does this not appear to be selling?

Buy the product,  try it and spread the word.

$AMRS These were full of our curlyhair product, amazing.

Also news on their latest line of products sound optimistic. BULLISH

sale

$AMRS Combo of sales momentum, improving margins (Barra Bonita), new molecule deal with potential for more, and other planned initiatives, means there won&#39;t be dilution.

$AMRS Regardless of whether the molecule licensing sale goes through or not, the stock will go up meaningfully.

short sale volume can be seen as a bullish indicator.

67% of shares sold were short sales and still bulls won this battle.

but revenue growth continues to be solid and they just had their record black Friday sales which will be reflected on next ER.

Yearly ST licence deals with increasing sales value combined with own increasing brand revenue and increase scaling producing for own brands and licence partners with an efficient and top notch production facility!!!

revenue

They are doing an excellent job expanding the market for our Reb M. This ingredient is expected to be in the top 3 ingredients for revenue by 2023 and is growing at a faster pace than we had planned.

Exactly what I expected, revenue was a bit higher than I anticipated 😅

All this should result in more revenue, royalties and profits 🚀 🚀 🚀.

$AMRS
This means that both amyris hemisqualane and amyris squalane will stay owned by Amyris and both can be commercialized individually or combined in a strategic transaction or more for more revenue streams. Success!

$AMRS 
About 4% of the hair care market share from the people with curly hair in USA will make the $140M revenue to Amyris from 4U by Tia Mowry. Success!

20M units sold in 2023 and $140M revenue from 4U by Tia Mowry is very possible. Success!

growth

Consumer brands are expected to continue to generate industry-leading growth in skin, hair, color cosmetics and baby care, as well as healthy aging.

Based on the previous growth trends, this will be easily exceeded.

100% growth rate in each brands

😎🚀

We all know that Amyris is a great biotech company with great growth, some parts of the business are growing above 100% and are already profitable this year.

If the deal happens this week, we are good and ER will happen on or around March 1st, it would be very forward looking and growth will continue.

$AMRS Post1 
IMO, Very interesting weekend reading, this year&#39;s growth will be spectacular in China.

Top Stocks matching your search for "director product"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Mar, 9, 2023

ADMP

Adamis Pharmaceuticals Corp

-50.14%

$0.21 - $0.10

Dec, 7, 2022

Divihomes is Now Live

AMRS

Amyris Inc

-15.82%

$1.58 - $1.33

Feb, 13, 2023

Jan, 12, 2023

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Mar, 9, 2023

ADMP

Adamis Pharmaceuticals Corp

-50.14%

$0.21 - $0.10

Dec, 7, 2022

AMRS

Amyris Inc

-15.82%

$1.58 - $1.33

Feb, 13, 2023

Jan, 12, 2023